The levels of telomere-binding proteins in human tumours and therapeutic implications

被引:14
作者
Cookson, J. C. [1 ]
Laughton, C. A. [2 ,3 ]
机构
[1] Pharminox Ltd, Nottingham NG1 1GF, England
[2] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England
[3] Univ Nottingham, Ctr Biomol Sci, Nottingham NG7 2RD, England
关键词
Telomere-binding proteins (TBPs); Telomere; Telomerase; Cancer; Antineoplastic agents; CELL LUNG-CANCER; MALIGNANT HEMATOPOIETIC-CELLS; GENE-EXPRESSION; IMMORTAL CELLS; DNA-DAMAGE; IN-VITRO; DYSFUNCTIONAL TELOMERES; CATALYTIC SUBUNIT; MYELOID-LEUKEMIA; GASTRIC-CANCER;
D O I
10.1016/j.ejca.2008.11.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumours require telomeric integrity to maintain viability, conferred by adequate length of telomeric DNA replenished by telomerase, and binding of telomere-binding proteins (TBPs), thus telomeres have received attention as an anticancer target. Levels of TBPs in tumour tissue may have implications for drug development if they render some cancers relatively more sensitive or resistant to telomere targeted agents. This review gives an overview of the studies examining the levels of TBPs in tumours and discusses possible reasons for differences in the findings, given the interplay between various factors determining telomere stability. Whether cancers with lower levels of TBPs will be more susceptible to therapies targeting telomere maintenance will require clinical trials of these novel therapies. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:536 / 550
页数:15
相关论文
共 79 条
[1]   Targeting assay to study the cis functions of human telomeric proteins:: Evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2 [J].
Ancelin, K ;
Brunori, M ;
Bauwens, S ;
Koering, CE ;
Brun, C ;
Ricoul, M ;
Pommier, JP ;
Sabatier, L ;
Gilson, E .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (10) :3474-3487
[2]   The structure and function of telomerase reverse transcriptase [J].
Autexier, Chantal ;
Lue, Neal F. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :493-517
[3]   Characterization of interactions between PinX1 and human telomerase Subunits hTERT and hTR [J].
Banik, SSR ;
Counter, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50) :51745-51748
[4]   Human Pot1 (Protection of telomeres) protein: Cytolocalization, gene structure, and alternative splicing [J].
Baumann, P ;
Podell, E ;
Cech, TR .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (22) :8079-8087
[5]   Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia [J].
Bellon, Marcia ;
Datta, Abhik ;
Brown, Megan ;
Pouliquen, Jean-Francois ;
Couppie, Pierre ;
Kazanji, Mirdad ;
Nicot, Christophe .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (09) :2090-2097
[6]   Telomere states and cell fates [J].
Blackburn, EH .
NATURE, 2000, 408 (6808) :53-56
[7]   The end of the (DNA) line [J].
Blackburn, EH .
NATURE STRUCTURAL BIOLOGY, 2000, 7 (10) :847-850
[8]   TELOMERASE ACTIVITY IN NORMAL AND MALIGNANT HEMATOPOIETIC-CELLS [J].
BROCCOLI, D ;
YOUNG, JW ;
DELANGE, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (20) :9082-9086
[9]   TELOMERE ELONGATION IN IMMORTAL HUMAN-CELLS WITHOUT DETECTABLE TELOMERASE ACTIVITY [J].
BRYAN, TM ;
ENGLEZOU, A ;
GUPTA, J ;
BACCHETTI, S ;
REDDEL, RR .
EMBO JOURNAL, 1995, 14 (17) :4240-4248
[10]   HTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia [J].
Campbell, LJ ;
Fidler, C ;
Eagleton, H ;
Peniket, A ;
Kusec, R ;
Gal, S ;
Littlewood, TJ ;
Wainscoat, JS ;
Boultwood, J .
LEUKEMIA, 2006, 20 (04) :671-679